Publicaciones en las que colabora con EMILIO BOUZA SANTIAGO (21)

2024

  1. COVID-19: On the threshold of the fifth year. The situation in Spain

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 1, pp. 17-28

  2. Meningococcal meningitis in Spain in the Horizon 2030: A position paper

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 4, pp. 285-298

  3. Respiratory syncytial virus: A new era

    Revista Espanola de Quimioterapia, Vol. 37, Núm. 2, pp. 134-148

  4. Unresolved issues in the diagnosis of catheter related candidemia: A position paper

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 1, pp. 1-16

2023

  1. Advantages and disadvantages of maintaining the mandatory use of masks in health centers and nursing homes in Spain. How and when is it justified to maintain it?

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 5, pp. 466-469

  2. Insights for COVID-19 in 2023

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 2, pp. 114-124

  3. Sexually transmitted infections in Spain: Current status

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 5, pp. 444-465

  4. Tuberculosis in Spain: An opinion paper

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 6, pp. 562-583

2022

  1. Booster or additional vaccination doses in patients vaccinated against COVID-19

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 35, Núm. 2, pp. 105-114

  2. COVID-19: Some unresolved issues

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 5, pp. 421-434

  3. Monkeypox in humans: a new outbreak

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 6, pp. 509-518

2018

  1. Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of Candida glabrata

    Medical Mycology, Vol. 56, Núm. 7, pp. 903-906

  2. Mutant prevention concentration and mutant selection window of micafungin and anidulafungin in clinical candida glabrata isolates

    Antimicrobial Agents and Chemotherapy, Vol. 62, Núm. 3

2017

  1. In vitro exposure to increasing micafungin concentrations easily promotes echinocandin resistance in Candida glabrata isolates

    Antimicrobial Agents and Chemotherapy, Vol. 61, Núm. 2

  2. Las placas de agar dextrosado de Sabouraud con fluconazol no son útiles para la detección de resistencia en Candida albicans

    Revista Espanola de Quimioterapia, Vol. 30, Núm. 2, pp. 127-130

2015

  1. Clusters of patients with candidaemia due to genotypes of Candida albicans and Candida parapsilosis: Differences in frequency between hospitals

    Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 677-683

2010

  1. Antimicrobial resistance among respiratory pathogens in Spain: Latest data and changes over 11 years (1996-1997 to 2006-2007)

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 7, pp. 2953-2959

  2. Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis

    Journal of Clinical Microbiology, Vol. 48, Núm. 2, pp. 456-459

2007

  1. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: Second National Study (2003)

    Revista Espanola de Quimioterapia, Vol. 20, Núm. 2, pp. 222-229

2006

  1. Combinations of PBPs and MurM protein variants in early and contemporary high-level penicillin-resistant Streptococcus pneumoniae isolates in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 57, Núm. 5, pp. 983-986